Alphyn Biologics, Inc.
- Biotech or pharma, therapeutic R&D
Alphyn is developing breakthrough therapies to treat the most challenging, severe, and common skin diseases. Our Zabalafin (AB-101) Drug Platform contains multiple bioactive compounds that power a new class of therapeutics capable of attacking disease in numerous ways. This unique approach enables the development of Multi-Target Therapeutics™ that target multiple diseases, and multiple symptoms and causes of each disease target.
Alphyn's lead drug candidate for atopic dermatitis (AD) completed Phase 2a clinical trials demonstrating efficacy against both the inflammatory and bacterial components of AD, with a strong safety profile for worry-free continuous and long-term use. Clinical trial results show superiority to current commercialized therapeutics and clinical-stage pipeline candidates.
)
)
){kind=logo}
){kind=logo}
){kind=logo}